KEYTRUDA: Which type of cancer did keytruda gain fda approval for initially

The FDA-approved drug Keytruda, developed by Merck & Co., has revolutionized cancer treatment by targeting specific proteins on immune cells to combat various types of cancer. Initially approved in 2014 for the treatment of metastatic melanoma, Keytruda’s successful clinical trials have since led to its approval for use in other conditions, such as non-small cell lung cancer, head and neck squamous cell carcinoma, and classical Hodgkin Lymphoma.